IP Library Patent Application 12735742
Patent Application
App. No. 12/735,742

IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/735,742
Abstract

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.

Claims (23)

1 . A method of manufacturing a medicament comprising formulating a medicament comprising at least one isolated immunogenic peptide said medicament preventing or treating in a subject, infection with an intracellular pathogen, the immunogenic peptide comprising (i) a T-cell epitope derived from an intracellular pathogen-associated antigen of said intracellular pathogen and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif.

2 . The method of claim 1 , said medicament inducing in a subject CD4+ regulatory T cells which are stimulating non-specific intracellular microbicidal mechanisms in cells of said subject infected with said intracellular pathogen.

3 . The method according to claim 1 , wherein said intracellular pathogen-associated antigen is derived from a virus, a bacterium, a mycobacterium or a parasite.

4 . The method according to claim 1 , wherein said C-(X)2-[CST] or [CST]-(X)2-C motif is adjacent to said T-cell epitope, or is separated from said T-cell epitope by a linker.

5 . The method according to claim 4 wherein said linker consists of at most 7 amino acids.

6 . The method according to claim 1 , wherein said C-(X)2-[CST] or [CST]-(X)2-C motif does not naturally occur within a region of 11 amino acids N- or C-terminally adjacent to the T-cell epitope in said intracellular pathogen-associated antigen.

7 . The method according to claim 1 , wherein said immunogenic peptide further comprises an endosomal targeting sequence.

8 . The method according to claim 1 , wherein said C-(X)2-[CST] or [CST]-(X)2-C motif is positioned N-terminally of the T-cell epitope.

9 . The method according to claim 1 , wherein at least one X in said C-(X)2-[CST] or [CST]-(X)2-C motif is Gly, Ala, Ser or Thr.

10 . The method according to claim 1 , wherein at least one X in said C-(X)2-[CST] or [CST]-(X)2-C motif is His or Pro.

11 . The method according to claim 1 , wherein at least one C in said C-(X)2-[CST] or [CST]-(X)2-C motif is methylated.

12 . The method according to claim 1 , wherein said immunogenic peptide is produced by chemical synthesis or by recombinant expression.

13 . A method for obtaining a population of intracellular pathogen-associated antigen-specific regulatory T cells with cytotoxic properties, the method comprising the steps of:

providing peripheral blood cells;

contacting said cells in vitro with an immunogenic peptide comprising (i) a T-cell epitope derived from an intracellular pathogen-associated antigen and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif; and

expanding said cells in the presence of Interleukin 2 (IL-2).

14 . A method for obtaining a population of intracellular pathogen-associated antigen-specific regulatory T cells with cytotoxic properties, the method comprising the steps of:

providing an immunogenic peptide comprising (i) a T-cell epitope derived from an intracellular pathogen-associated antigen and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif;

administering said immunogenic peptide to a subject; and

obtaining said population of intracellular pathogen-associated antigen-specific regulatory T cells from said subject.

15 . A population of intracellular pathogen-associated antigen-specific regulatory T cells with cytotoxic properties obtainable by the method according to claim 13 .

16 . Use of A method of manufacturing a medicament comprising formulating a medicament comprising the population of intracellular pathogen-associated antigen-specific regulatory T cells according to claim 15 , said medicament preventing or treating infection with said intracellular pathogen.

17 . An isolated immunogenic peptide comprising a T-cell epitope from an intracellular pathogen-associated antigen and, adjacent to said T-cell epitope or separated from said T-cell epitope by a linker, a C-(X)2-[CST] or [CST]-(X)2-C motif.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2010
From: SAINT-REMY, JEAN-MARIE
To: LIFE SCIENCES RESEARCH PARTNERS VZW
Reel/Frame 025452/0475 →